Exclusive Summary

• - Differentiated first-line option for EGFR L858R and uncommon mutations (G719X/S768I/L861Q), directly addressing current SOC gaps.
• - Backed by NMPA-CDE Breakthrough Therapy and originator patents, with a clear near- to mid-term global “no-generic” window suitable for distribution.
• - Tangible annual target pool of ~150–200k L858R and ~40–70k uncommon-mutation patients worldwide.
• - 40/80 mg strengths enable individualized titration and AE management, improving real-world adherence and access.
• - Well-suited for rapid launch via reliance/abbreviated pathways in APAC, LATAM, and MENA under a Distribution model.